logo
First Alzheimer's blood test available in US in June

First Alzheimer's blood test available in US in June

Straits Times21-05-2025

The first blood test to help diagnose Alzheimer's disease will be available from late June in the US. PHOTO: ISTOCKPHOTO
WASHINGTON – The first blood test to help diagnose Alzheimer's disease will be available from late June in the US following regulatory clearance for its use last week, according to the Japanese company behind the innovation.
The test will initially be available at about 50 American research institutes and hospitals that specialise in Alzheimer's disease, Mr Goki Ishikawa, head of Fujirebio Holdings Inc., a unit of Japan's H.U. Group Holdings Inc., said in an interview on May 20. It's partnering with bigger rivals like Beckman Coulter Inc. to help develop and manufacture their products, he said.
The Food and Drug Administration cleared the blood test to help diagnose Alzheimer's disease last week, potentially making it easier to find and treat patients with the memory-robbing disease that affects nearly seven million Americans.
The test was cleared for use in people at least 55 years old and who exhibit signs of the disease. It is designed to detect amyloid, a protein that can build up in the brain and is a hallmark of Alzheimer's, the most common form of dementia in the elderly.
The process, which takes roughly 30 minutes from drawing the blood to diagnosis, will be available to patients at a fraction of the cost of a PET scan. The method is viewed as a critical step in making new types of Alzheimer's treatments widely accessible.
Until now, patients typically have to get a specialised PET scan to detect amyloid in their brains or undergo cerebrospinal fluid tests, both of which are more expensive and invasive. The lack of quick and easy tests has until now slowed the rollout of new Alzheimer's drugs like Eisai Co. and Biogen Inc.'s Leqembi and Eli Lilly & Co.'s Kisunla.
The company plans to file data to seek approvals in Japan as early as August and Europe within this year, Mr Ishikawa said. In China, Fujirebio's undisclosed partner will probably submit data to regulators next year, he added. In India, it partners with Agappe Diagnostics Ltd.
'We have a presence in Japan but that's not necessarily the case in markets overseas,' said Mr Ishikawa. 'We can't get the market shares by ourselves, but if we supply the raw materials to partners, we can benefit through them.' BLOOMBERG
Join ST's Telegram channel and get the latest breaking news delivered to you.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Asia healthcare assets risk overvaluation as private investors scoop them up
Asia healthcare assets risk overvaluation as private investors scoop them up

Business Times

time3 hours ago

  • Business Times

Asia healthcare assets risk overvaluation as private investors scoop them up

[SINGAPORE] As private equity (PE) investors pour money into Asian healthcare, some observers are concerned that this sector could soon overheat. Some recent deals this year include KKR's US$400 million purchase of a 54 per cent stake in India's Healthcare Global Enterprises in February. In Singapore, another American PE firm TPG took Catalist-listed nursing operator Econ Healthcare private in a deal worth nearly S$88 million. When the proposed transaction was announced in February, the offer price represented a 20 per cent premium to Econ's last traded share price on Jan 14. 'We are not the only ones to see the opportunity of healthcare in Asia, and, as a consequence, valuations can be high,' Abrar Mir, co-founder and managing partner of healthcare-focused PE firm Quadria Capital, told The Business Times. Other factors driving investors to the healthcare sector – perceived as defensive, and so able to withstand the ups and downs of economic cycles – is the ongoing macroeconomic uncertainty and volatility in global financial markets. This is particularly so in Asia, where investors have been diversifying away from China in the last few years, to avoid being caught in the cross hairs of the nation's tensions with the United States. As PE firms and their investors focus on acquiring companies independent of China, more deals have been transacted in Japan, South Korea and India, where the demand for healthcare and related services is strong and largely unaffected by tariffs. 'Japan has always been a stable healthcare market, and particularly because of (its) demographics and medical needs,' said David Braga Malta, thematic health principal at Pictet Alternative Advisors, to BT. 'We saw some of the mid-sized Japanese pharma companies being very acquisitive in the recent months and years... And of course, we saw the boom in the IPO (initial public offering) markets in India last year.' BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Asia's appeal even drew European PE investors to buy South Korean assets for the first time in 2024, he added. Last September, France's Archimed spent US$742 million buying Jeisys Medical, a South Korean developer of aesthetic medicine devices. Like shopping in Louis Vuitton 'One of the key things that I always say to my investors is that... investing in healthcare in Asia is like shopping in Louis Vuitton. So, as an investor, we have to navigate that, be careful not to overpay,' said Quadria Capital's Mir. According to a Bain & Co report, global PE deal value in the sector surged last year to an estimated US$115 billion – the second highest on record. Bain added that PE firms continue to invest in healthcare in the Asia-Pacific, where deal values have been steadily rising since 2016. Industry participants named India as the country attracting the most number of healthcare PE investors. An ageing population, rising incidence of chronic disease and growing awareness of preventive care, combined with the opening up of its insurance market to foreign investment, are making India stand out. Bain estimated that the country made up 26 per cent of the 62 deals transacted in the Asia-Pacific last year. PwC said its health industries practice in India hit a double-digit compound annual growth rate in the past few years as well. But Ling Tok Hong, deals and private equity leader at PwC, cautioned that 'this continued focus on the India market could make it more susceptible to overvaluation if investors are not cautious'. South-east Asia's healthcare sector is also attracting PE investors, leading to 'unprecedented valuations' of Ebitda multiples in their 20s, noted Ling. He was referring to earnings before interest, taxes, depreciation and amortisation. Room for growth; returns still strong Despite the rising valuations in Asia's healthcare sector, market participants point out that there is still room for growth, a key factor backing the higher valuations in the first place. The sector offers attractive long-term growth prospects as the supply of quality healthcare assets in the region is not growing quickly enough to meet demand. In markets such as South-east Asia, 'the number of large, institutionally ready platforms is still limited. This scarcity has helped sustain high entry multiples in recent years', said Alex Boulton, partner and Asia-Pacific lead for healthcare and life sciences private equity at Bain. He pointed out that South-east Asia's healthcare sector relies heavily on private players. For instance, the private sector accounts for roughly half of all hospital beds in Indonesia and the Philippines. 'That structural dynamic creates an enduring role for private capital in expanding and upgrading healthcare infrastructure.' Market participants emphasise that Asian healthcare is not in bubble territory. Boulton pointed out that even with rising valuations, healthcare PE in Asia is still delivering strong returns. Bain's analysis shows that from 2018 to 2023, the median multiple on invested capital (MOIC) for exited healthcare deals in the region was approximately 2.6 – meaning that a US$1 million investment generated a return of US$2.6 million. This compares with the global median MOIC of around two. 'That speaks to the sector's ability to compound value through growth and operational improvement, even in a more expensive entry environment,' noted Boulton. That said, while returns are likely to remain strong in the future, the median MOIC may not be sustained at these levels, he added. Thus, market players said, investors will need to have a clear plan to create meaningful impact and value over the life of their investments.

NIH scientists speak out over estimated $12 billion in Trump funding cuts
NIH scientists speak out over estimated $12 billion in Trump funding cuts

Straits Times

time4 hours ago

  • Straits Times

NIH scientists speak out over estimated $12 billion in Trump funding cuts

The National Institutes of Health (NIH) Gateway Center is seen in the rain in Bethesda, Maryland, U.S., June 8, 2025. REUTERS/Elizabeth Frantz Anna Culbertson, a former employee at the National Institute of Allergy and Infectious Diseases, sits for a portrait in Bethesda, Maryland, U.S., June 8, 2025. REUTERS/Elizabeth Frantz Jenna Norton, an employee at the National Institute of Diabetes and Digestive and Kidney Diseases, sits for a portrait in Bethesda, Maryland, U.S., June 8, 2025. REUTERS/Elizabeth Frantz Ian Morgan, an employee at the National Institute for General Medical Sciences, sits for a portrait in Bethesda, Maryland, U.S., June 8, 2025. REUTERS/Elizabeth Frantz National Institute of Diabetes and Digestive and Kidney Diseases employee Jenna Norton, National Institute for General Medical Sciences employee Ian Morgan and National Institute of Allergy and Infectious Diseases former employee Anna Culbertson sit for a portrait in Bethesda, Maryland, U.S., June 8, 2025. REUTERS/Elizabeth Frantz Dozens of scientists, researchers and other employees at the U.S. National Institutes of Health issued a rare public rebuke Monday criticizing the Trump administration for major spending cuts that 'harm the health of Americans and people across the globe,' politicize research and 'waste public resources.' More than 60 current employees sent their letter to NIH director Dr. Jay Bhattacharya, U.S. Health Secretary Robert F. Kennedy Jr. and members of Congress who oversee NIH. Bhattacharya is scheduled to testify Tuesday at the U.S. Senate appropriations committee about his agency's budget. Overall, more than 340 current and recently terminated NIH employees signed the letter, about 250 of them anonymously. In their letter, NIH staff members said the agency had terminated 2,100 research grants totaling about $9.5 billion and an additional $2.6 billion in contracts since President Donald Trump took office Jan. 20. The contracts often support research, from covering equipment to nursing staff working on clinical trials. These terminations "throw away years of hard work and millions of dollars" and put patient health at risk, the letter said. NIH clinical trials "are being halted without regard to participant safety, abruptly stopping medications or leaving participants with unmonitored device implants." Officials at the U.S. Department of Health and Human Services, which oversees NIH, didn't immediately respond to a request for comment. In prior remarks, Bhattacharya has pledged support for Kennedy's Make America Healthy Again agenda, and he has said that means focusing the federal government's "limited resources" directly on combating chronic diseases. At his Senate confirmation hearings in March, Bhattacharya said he would ensure scientists working at NIH and funded by the agency have the necessary resources to meet its mission. NIH is the world's largest public funder of biomedical research and has long enjoyed bipartisan support from U.S. lawmakers. The Trump administration has proposed cutting $18 billion, or 40%, from NIH's budget next year, which would leave the agency with $27 billion. Nearly 5,000 NIH employees and contractors have been laid off under Kennedy's restructuring of U.S. health agencies, according to NIH staff. Dr. Jenna Norton, a program director within NIH's division of kidney, urologic and hematologic diseases, was one of 69 current employees who signed the letter as of early Monday. She said speaking out publicly was worth the risk to her career and family. "I am much more worried about the risks of not speaking up," Norton said. "There are very real concerns that we're being asked to do likely illegal activities, and certainly unethical activities that breach our rules." About 20 NIH employees who were recently terminated as probationary workers or "subject to reductions in force" added their names to the letter. In the letter, Norton and other NIH employees asked Bhattacharya to restore grants that were delayed or terminated for political reasons, where officials ignored peer review to "cater to political whims." They wrote that Bhattacharya had failed to uphold his legal duty to spend congressionally appropriated funds. One program director at the NIH's National Cancer Institute, who asked not to be identified for fear of retaliation, said she has repeatedly been asked to cancel research grants for no valid reason and in violation of agency rules. She said she fears she could become the target of lawsuits from grantees challenging those decisions. Dr. Benjamin Feldman, a staff scientist and core director at NIH's Institute of Child Health and Human Development, said he and other researchers want to work with Bhattacharya on reversing the cuts and restoring the NIH as a "beacon for science around the world." "This is really a hit to the whole enterprise of biomedical research in the United States," Feldman said. Dr. Ian Morgan, a postdoctoral fellow at the NIH, signed the letter and said he has heard from university researchers about patients losing access to novel cancer treatments in clinical trials due to the uncertainty over NIH funding. He also worries about the long-term effect from gutting NIH's investment in basic science research that can lead to lifesaving treatments years later. The NIH employees, based in Bethesda, Maryland, named their dissent the "Bethesda Declaration," modeled after Bhattacharya's Great Barrington Declaration in 2020 that called on public health officials to roll back lockdowns during the COVID-19 pandemic. "Our hope is that by modeling ourselves after the Great Barrington Declaration that maybe he'll see himself in our dissent," Norton said. REUTERS Join ST's Telegram channel and get the latest breaking news delivered to you.

Early detection of ‘bubble boy disease' helps save lives of newborns
Early detection of ‘bubble boy disease' helps save lives of newborns

Straits Times

time6 hours ago

  • Straits Times

Early detection of ‘bubble boy disease' helps save lives of newborns

Mannat Singh was only six days old when he was diagnosed with Severe Combined Immunodeficiency (SCID). ST PHOTO: NG SOR LUAN Medical Mysteries Early detection of 'bubble boy disease' helps save lives of newborns Medical Mysteries is a series that spotlights rare diseases or unusual conditions. SINGAPORE – Mannat Singh was only six days old when he was diagnosed with Severe Combined Immunodeficiency (SCID). This meant that he was born without a functioning immune system, making him highly vulnerable to even the common flu. Without treatment, Mannat would not have made it past his first birthday. His mother Harminder Kaur, 39, a nurse, recalled the guilt and fear she felt 'because I made him this way'. SCID is a rare life-threatening genetic disorder that affects one in 50,000 babies worldwide, with one new case born in Singapore every two years. 'It did not help our state of mind when his odds were stacked against him,' said her husband Harminder Singh, 39, an IT consultant. It is also known as the 'bubble boy disease' after David Vetter, an American boy with the disease who captured the world's attention for living all his life in a sterile plastic enclosure – his 'bubble'. At the time of his birth in 1971, a bone marrow transplant from an exact matched donor was the only cure for SCID, but there was no match available in David's family. In 1984, four months after receiving a bone marrow transfusion via a new technique, the 12-year-old died from lymphoma, a cancer later traced to a dormant Epstein-Barr virus in the donor bone marrow. As for baby Mannat, he had Artemis SCID, a rare form of recessive radiosensitive SCID, which meant he could not be treated with radiation or have certain scans done. Mannat Singh was born without a functioning immune system, making him highly vulnerable to even the common flu. ST PHOTO: NG SOR LUAN Memories of what the couple went through with their younger son brought back tears to Mr Singh, who said: 'We were prepared to do whatever we could to give Mannat the best chance at life. We took a step at a time, discussing putting him on chemotherapy and deferring to the experts.' Fortunately for Mannat, his condition was picked up at the KK Women's and Children's Hospital (KKH) through the National Expanded Newborn Screening (Nens) programme. The programme, which started in 2006 with the aim of screening all babies born in Singapore for metabolic and heritable diseases, was expanded in 2019 to include five other treatable serious childhood-onset conditions such as SCID and cystic fibrosis. In 2024, all newborns at KKH were screened under Nens, while the national screening rate in Singapore is 96 per cent. This involves pricking the baby's heels to collect a blood sample between 24 and 72 hours after birth. Screening for SCID involves checking the baby's bloody for DNA fragments called T-cell receptor excision circles (Trecs), which show that the immune system is making T-cells properly, said geneticist from KKH Ting Teck Wah. The test does not confirm an SCID diagnosis, but abnormalities such as low or absent Trecs signals that the baby needs to go through more testing, he said. After screening almost 178,000 babies since 2019, Nens has picked up two babies positive for SCID, Dr Ting added. Dr Bianca Chan, a consultant with the rheumatology and immunology services at KKH, said the only real curative treatment for SCID is a bone marrow transplant from a healthy donor. Stem cells from the bone marrow from a health donor can develop into infection-fighting T-cells, helping babies with SCID build a functioning immune system. 'The highest success is when it is performed within the first three to four months of life, before the baby develops significant infections. This makes SCID screening at birth crucial for early diagnosis to actively prevent infection,' she said. Dr Chan added that if the baby has an active infection before the transplant, its survival rate even with transplant is only 50 per cent 'because it becomes very, very difficult to have a successful transplant'. Mannat Singh and parents Harminder Kaur and Harminder Singh, with KKH doctors (back row, from left) Dr Michaela Seng, Dr Ting Teck Wah and Dr Bianca Chan. ST PHOTO: NG SOR LUAN Dr Michaela Seng, a senior consultant with the haematology and oncology service at the hospital, said a programme is immediately put in place to protect the child from infections before doctors prepare for donor selection. 'We meet the parent to explain the implications of the diagnosis and tell them they are typically appropriately suitable as potential donors. We also go through the process of harvesting and processing the donor stem cells, how the lab then receives these stem cells ... and prepare small bags of what we call memory T-cells that help fight infection,' she said. 'During this time, the baby, is admitted to the transplant unit and undergoes complete isolation. For seven days, he is given conditioning therapy, which is chemotherapy that is tailored to the size and the weight of the baby to allow us to clear unnecessary cells that would prevent successful engraftment of the donor stem cells. The donor cells are then infused, and we wait for the transplant to take effect,' she added. Mannat became the first newborn in Singapore to have his SCID diagnosed at birth and the first to receive a stem cell transplant – from his mother's bone marrow – before the symptoms emerge. Today, at 19 months, Mannat is healthy and asserting himself with his parents and older brother Birakaal, aged four. 'I feel now that life has returned to normal and we have put the past behind us. We are now looking forward to having the boys grow up healthy and happy,' Ms Kaur said. Join ST's WhatsApp Channel and get the latest news and must-reads.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store